MacroGenics (NASDAQ:MGNX) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Tuesday.
MGNX has been the subject of a number of other reports. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. ValuEngine cut MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Citigroup raised their price objective on MacroGenics from $18.00 to $22.00 and gave the company a “neutral” rating in a research report on Friday, November 10th. Zacks Investment Research cut MacroGenics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 6th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $30.60.
Shares of MacroGenics (NASDAQ:MGNX) opened at $23.85 on Tuesday. MacroGenics has a 52-week low of $14.36 and a 52-week high of $23.93. The stock has a market capitalization of $878.22, a P/E ratio of -5.31 and a beta of 2.79.
Several hedge funds and other institutional investors have recently made changes to their positions in MGNX. Legal & General Group Plc increased its stake in shares of MacroGenics by 4.3% during the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 328 shares during the period. Parametric Portfolio Associates LLC bought a new position in shares of MacroGenics during the second quarter worth approximately $203,000. Teacher Retirement System of Texas bought a new position in shares of MacroGenics during the fourth quarter worth approximately $225,000. Virtu KCG Holdings LLC bought a new position in MacroGenics during the 2nd quarter worth $232,000. Finally, Citigroup Inc. increased its stake in MacroGenics by 8.4% during the 2nd quarter. Citigroup Inc. now owns 18,975 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 1,466 shares during the period. Institutional investors own 83.18% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BidaskClub Upgrades MacroGenics (MGNX) to “Hold”” was published by Week Herald and is the property of of Week Herald. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://weekherald.com/2018/02/15/bidaskclub-upgrades-macrogenics-mgnx-to-hold.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.